The European Hematology Association (EHA)

An update from the phase 1b/2 CARTITUDE study reveals early, deep, and durable responses and a manageable safety profile from treatment of patients with advanced RRMM with JNJ-4528 CAR T-cells. Read More ›

Based on early results of a dose-escalation study, teclistamab demonstrated an overall response rate of 67% at the highest dose, as well as reasonable tolerability with low incidence of high-grade cytokine release syndrome in patients with advanced relapsed/refractory multiple myeloma. Read More ›

Tyrosine kinase inhibitors (TKIs) have dramatically improved survival in chronic myeloid leukemia (CML). Most patients achieve deep molecular responses, such that TKIs can be safely and successfully stopped. However, specific preconditions for stopping TKI treatment in CML have not been defined.

Read More ›

Nikhil Munshi talks about modifying treatment to patients' expectations and what they can tolerate. Read More ›

Nikhil Munshi would like to see more emphasis put into studies to provide reasonable costs for treatment so as to relieve the financial burden of some patients. Read More ›

Nikhil Munshi believes caregivers should be informed about the newer medicines so they can be aware of potential side effects as well as medicine's responsibility to take a holistic approach to patients' lives post-treatment. Read More ›

Joseph Connors, MD, explains how the understanding of the disease has evolved leading to the categorization of subsets and consequently resulted in the development of newer therapies to address these subsets. Read More ›

Leaders in hematology will present data from 6 research efforts that have been recognized as top abstracts in this year’s Congress. Leukemias – acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML) –feature prominently. Read More ›

This poster session spotlights clinical trial data for commercialized and emerging therapies with activity in adults and children with acute lymphoblastic leukemia (ALL). Novel therapies include inotuzumab ozogamicin, ponatinib, and bortezomib. Read More ›